TRILIO
KUBECON + CLOUDNATIVECON EUROPE— Trilio , a leading provider of cloud-native data protection, today announced a technical preview of a new “Continuous Restore” capability that is being showcased to the cloud-native community at the KubeCon + CloudNativeCon Europe conference. Continuous Restore offers faster levels of replication, restoration and migration of data and metadata from any storage or cloud platform to another, dramatically improving recovery times for cloud-native applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005514/en/
Entirely storage-, cloud- and distribution-agnostic, Trilio’s “Continuous Restore” capability will enable users to continuously stage data at multiple and heterogeneous clouds. This means that applications—regardless of where they reside—will be able to tap into that data and be brought online in seconds, achieving exceptional levels of Recovery Time Objectives (RTO). The capability will be introduced as part of the TrilioVault for Kubernetes cloud-native data protection and management platform.
“Distributed environments consisting of core, edge and cloud resources are becoming the predominant architecture for enterprises today,” said Murali Balcha, Founder and CTO of Trilio. “Companies frequently need to move stateful applications and their data volumes among these diverse environments to achieve cost-efficiency, performance, security and disaster recovery imperatives. Unfortunately, no easy-to-use, affordable solution for continuous data volume replication across heterogeneous infrastructure environments exists today.”
“Trilio’s Continuous Restore capability enables migration and replication of stateful applications in seconds or minutes so that all companies can protect and use their data anywhere—regardless of what the application runs on or where the data is stored,” continued Balcha. “This provides organizations the ability to meet leading levels of application uptime, achieve Service Level Agreements (SLAs) expected of production-grade applications—all at an affordable cost. Continuous Restore is a game-changer that will make today’s modern businesses even more competitive and resilient.”
***To see a Demo of Continuous Restore, visit Trilio at Booth P11 at KubeCon + CloudNativeCon Europe or schedule a meeting with our K8s Experts ***
Use cases for the Continuous Restore capability include:
1. Disaster Recovery: Users will be able to achieve availability objectives and recover from outages or failures in a matter of seconds or minutes rather than days or weeks. Using Continuous Restore, Recovery Time Objectives (RTO) will improve by over 80% versus traditional methods.
2. Application Migrations : Continuous Restore allows IT teams to optimize performance and achieve better Total Cost of Ownership (TCO) by choosing the infrastructure best suited to current needs. The Continuous Restore capability will also enable organizations to unify their infrastructure, especially those that have grown quickly and adopted a variety of compute platforms and storage solutions to meet unique needs. Continuous Restore will make possible tremendously fast application mobility across infrastructure silos, making them silos no more.
3. Testing/Development: Developers can increase the velocity of CI/CD pipelines by staging data for multiple test/dev environments. These test/dev environments can be spun up in seconds with continuously replicated production data and accelerating the push of validated changes into production. In fact, DevOps teams can use this capability to test their “restore” protocols to ensure that restore will work when needed.
4. Data Curation from Edge Clouds: As distributed environments proliferate in the future, massive amounts of data will be collected at “the edge,” and this information from diverse architectures will need to be rapidly replicated and moved throughout distributed systems where it can be assimilated and centrally analyzed by any number of different applications.
Attend Trilio’s Session: “ Cloud-Native App Recoverability & Portability in a Matter of Seconds thru the Unification of Information Silos'' on Thursday May 19 3pm CET at the Microsoft Azure Booth P12. Join Ben Morrison, solution architect at Trilio, for his presentation and demo showcasing Trilio's capability for migrating a stateful application from on-prem Red Hat OpenShift to Azure AKS in a matter of seconds — highlighting the flexibility and speed enabled by the TrilioVault for Kubernetes platform.
Continuous Restore is a capability within TrilioVault for Kubernetes and will be made generally available as part of a product release in Q3’22. For those that want to preview or test the capability, please contact Trilio .
About Trilio
Trilio is a leader in cloud-native data protection for Kubernetes, OpenStack and Red Hat Virtualization environments. Our TrilioVault technology is trusted by cloud infrastructure operators and developers for backup and recovery, migration and application mobility. Customers in telecom, defense, automotive and financial services leverage TrilioVault to recover from disasters, migrate workloads, move workloads to new infrastructure and migrate to new software distributions. Trilio.io , Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005514/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ViaLase Announces First Patient Treated in IDE Clinical Trial Evaluating Its Femtosecond Laser Trabeculotomy for Open-Angle Glaucoma3.12.2025 14:00:00 CET | Press release
Prospective, randomized controlled trial compares novel femtosecond laser procedure to selective laser trabeculoplasty (SLT), advancing path to US commercialization ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) clinical trial evaluating the company’s femtosecond laser trabeculotomy procedure for the management of glaucoma, a lifelong, progressive, and incurable disease that remains a leading cause of irreversible blindness worldwide. This prospective, multicenter, randomized, controlled trial evaluates the ViaLase procedure in comparison to selective laser trabeculoplasty (SLT), the current standard laser treatment for reducing intraocular pressure (IOP). This trial was designed in consultation with the FDA to achieve clearance and commercialization in the U.S. and thus represents one of the most rigorous e
Winchester Interconnect Launches LiteSPEed™ Cable: Faster, Lighter, Simpler Connectivity for Mission-Critical Systems3.12.2025 14:00:00 CET | Press release
Winchester Interconnect, an Aptiv company and leading supplier of high-performance interconnect solutions, today introduced LiteSPEed™ Cable, a next-generation single-pair Ethernet (SPE) solution that delivers 10-gigabit data rates in a dramatically smaller, lighter design. Built for the increasingly connected and space-constrained environments of aerospace, defense, industrial automation and next-generation mobility, LiteSPEed™ helps customers move more data with less cable, reducing weight, complexity, and cost while increasing system performance and reliability. “As systems become more intelligent and interconnected, engineers need lighter, more efficient ways to deliver power and data,” said Juan Contreres, director of product management. “LiteSPEed™ gives them a rugged, high-speed Ethernet solution that simplifies installation without compromising performance.” With advanced sensors, real-time analytics, and distributed control systems proliferating across industries, cabling has
Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides3.12.2025 14:00:00 CET | Press release
Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible individuals, and implementation varies between countries. The model concept was initiated as part of Owkin’s ongoing partnership with Gustave Roussy and Centre Léon Bérard through PortrAIt, a French consortium dedicated to advancing precision medicine with AI-enabled digital pathology. Fostered through collaboration with AstraZeneca, as announced in October 2024, the development of BRCAura aims to accelerate and expand identification of BRCA mutations in patients with breast cancer. Strong validation across internationa
Adva Network Security achieves BSI approval for PQC-encrypted edge networking device3.12.2025 14:00:00 CET | Press release
News summary: Critical infrastructure, defense and governments need quantum-safe encryption at the edge to neutralize ‘harvest-now, decrypt-later’ risks FSP 150-XG118Pro (CSH) delivers quantum-safe encryption via software update, enabling seamless upgrades with no hardware changes BSI approval confirms the device’s compliance for government and defense use Adva Network Security today announced that the FSP 150-XG118Pro (CSH) 10Gbit/s edge device now delivers quantum-safe encryption based on post-quantum cryptography (PQC). This enhancement enables operators of critical network infrastructure (CNI) to secure data in motion and build future-ready networks. Certified by the German Federal Office for Information Security (BSI), the solution’s Ethernet encryption offers PQC crypto-agility via a software update, eliminating the need for hardware changes. With its new capabilities, the FSP 150-XG118Pro (CSH) is ideally suited for diverse high-security environments, ranging from national infra
Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing3.12.2025 14:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President: Toshiaki Nagasato) today announced a strategic equity investment in Lyric Bio, Inc. (Head Office: San Carlos, USA, founded by Chief Executive Officer: Kayj Shannon and Chief Scientific Officer Melanie Matheu). Through this investment, Meiji Seika Pharma seeks to accelerate the early-stage development of Lyric Bio’s innovative platform for producing human immunoglobulin (IVIg), explore donation-independent manufacturing methods, and lay the groundwork for a more resilient, high-quality supply of plasma-derived therapeutics to meet increasing global demand. Lyric Bio is developing a next-generation biomanufacturing platform for IVIg production. The company’s approach uses tissue-mimicking bioreactors built on a proprietary laser-printed cellular substrate that enables ultra high-density cell growth and has the potential to deliver more than 1,000 IVIg doses from a single donor. This investment will accelerate Lyric Bio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom